Immunocore stock reaches a 540 patient trial milestone

Immunocore (ISIN GB00BL963Z95) stock is tied to a 540 patient clinical milestone after the company completed target enrollment in its Phase 3 TEBE-AM trial on September 14, 2026. The study evaluates KIMMTRAK in previously treated advanced melanoma, giving the biotechnology company a defined data catalyst while its commercial business continues to fund development.

TEBE-AM reaches 540 patients

According to Immunocore in its September 14, 2026 Form 8-K, TEBE-AM is a registrational Phase 3 study testing tebentafusp alone and with pembrolizumab against investigator choice. Overall survival is the primary endpoint, so the enrollment milestone moves the program from recruitment toward the next evidence stage.

The trial focuses on HLA-A*02:01-positive patients with unresectable or metastatic melanoma whose disease progressed after prior therapy. That design gives the 540-patient cohort a direct connection to a defined treatment population rather than a broad early-stage research effort.

Q2 revenue reached USD 115.93 million

Investing.com reported Q2 2026 revenue of USD 115.93 million and net income of minus USD 0.81 million. Diluted EPS was minus USD 0.02, putting operating progress beside continuing investment in the clinical pipeline.

The quarter also provides a quantified comparison with expectations. MarketBeat said the company reported a loss of USD 0.02 per share against a consensus loss of USD 0.01 for the quarter, a USD 0.01 miss.

Analyst target averages USD 56.38

MarketBeat reported a Moderate Buy consensus from 12 ratings firms on September 22, 2026, with an average 12-month price target of USD 56.38. The same report cited JPMorgan's August 21, 2026 initiation at Overweight with a USD 50.00 target, showing that published targets still span different views of the clinical pipeline.

That spread matters because TEBE-AM is only one of three late-stage programs discussed by management. A successful outcome could expand the role of KIMMTRAK in melanoma, while an unfavorable result would leave the valuation more dependent on the existing uveal melanoma franchise and additional studies.

Market value marks the next checkpoint

Immunocore had a market capitalization of USD 1.5 billion on September 30, 2026. The company is listed on Nasdaq under IMCR, and the combination of the 540-patient enrollment milestone, USD 115.93 million in Q2 revenue and the USD 0.01 EPS miss defines the stock's current balance between clinical progress and execution risk.

More news and analyses on Immunocore stock